Drug Trial Radar · NCT04820439
Pharmacokinetic Study of Recombinant Monoclonal Antibody Against Human Epidermal Growth Factor Receptor Injection
Last checked: Nov 19, 2026Latest source record: Mar 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
88
Actual
Start
Oct 13, 2020
Primary completion
Feb 1, 2021
Study completion Mar 13, 2021
Sponsor
- Lead sponsor
- The Affiliated Hospital of Qingdao UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 29, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 40 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study was designed as a randomized, double-blind, parallelity-controlled study.Eighty-eight healthy male subjects (44 in each group) will be enrolled in this study.The aim of this clinical trial is to evaluate pharmacokinetic similarity between recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627) and Perjeta ® in a single intravenous infusion in healthy male subjects.
Conditions
- Healthy Volunteers
Interventions
recombinant monoclonal antibody against human epidermal growth factor receptor injection (HS627)Drug
A single intravenous infusion of HS627 420mg
Perjeta ®Drug
A single intravenous infusion of Perjeta ®420mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under the plasma concentration versus time curve (AUC)0-∞Time frame: 150 days
- Area under the plasma concentration versus time curve (AUC)0-tTime frame: 150 days
- Peak Plasma Concentration (Cmax)Time frame: 150 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Phase I Clinical Research Center
Qingdao, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.